Pfizer
PFE
2,323 hedge funds and large institutions have $142B invested in Pfizer in 2019 Q3 according to their latest regulatory filings, with 100 funds opening new positions, 989 increasing their positions, 1,011 reducing their positions, and 137 closing their positions.
2% less repeat investments, than reductions
Existing positions increased: 989 | Existing positions reduced: 1,011
1.3% less ownership
Funds ownership: 76.85% → 75.55% (-1.3%)
2% less funds holding
Funds holding: 2,378 → 2,323 (-55)
19% less call options, than puts
Call options by funds: $1.16B | Put options by funds: $1.43B
19% less capital invested
Capital invested by funds: $176B → $142B (-$33.5B)
27% less first-time investments, than exits
New positions opened: 100 | Existing positions closed: 137
59% less funds holding in top 10
Funds holding in top 10: 199 → 81 (-118)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.53B |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$493M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$244M |
| 4 |
Sanders Capital
West Palm Beach,
Florida
|
+$185M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$172M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.3B |
| 2 |
JP Morgan Chase
New York
|
-$760M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$386M |
| 4 |
APG Asset Management
Amsterdam,
Netherlands
|
-$383M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$374M |
PFE Hedge Fund Activity: Q3 2019 in Review
2,323 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q3 2019, worth a combined $142B — down 19% from $176B a quarter earlier.
Sellers outnumbered buyers: 137 funds closed out of PFE and 100 opened new positions — a net loss of 37 holders — while 1,011 trimmed existing stakes and 989 added.
The largest buyer was Wellington Management Group, adding an estimated $1.53B. The largest seller was T. Rowe Price Associates, cutting an estimated $1.3B.
- 2,323 institutional investors held Pfizer (PFE) as of Q3 2019, down from 2,378 in Q2 2019.
- Funds reported $142B of Pfizer stock for Q3 2019, down 19% quarter-over-quarter.
- 100 funds opened new Pfizer positions in Q3 2019 and 137 closed out, a net change of -37 holders.
- The largest Pfizer buyer in Q3 2019 was Wellington Management Group, an estimated $1.53B added.
- The largest Pfizer seller in Q3 2019 was T. Rowe Price Associates, an estimated $1.3B sold.
Based on aggregated 13F filings for Q3 2019.